|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GSTZ1 |
Gene summary for GSTZ1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GSTZ1 | Gene ID | 2954 |
| Gene name | glutathione S-transferase zeta 1 | |
| Gene Alias | GSTZ1-1 | |
| Cytomap | 14q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | O43708 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2954 | GSTZ1 | HCC1_Meng | Human | Liver | HCC | 4.08e-76 | 2.02e-01 | 0.0246 |
| 2954 | GSTZ1 | HCC2_Meng | Human | Liver | HCC | 1.66e-07 | 6.70e-02 | 0.0107 |
| 2954 | GSTZ1 | HCC2 | Human | Liver | HCC | 1.05e-06 | 2.64e+00 | 0.5341 |
| 2954 | GSTZ1 | Pt13.b | Human | Liver | HCC | 7.73e-06 | 1.80e-01 | 0.0251 |
| 2954 | GSTZ1 | S014 | Human | Liver | HCC | 5.86e-11 | 4.07e-01 | 0.2254 |
| 2954 | GSTZ1 | S015 | Human | Liver | HCC | 2.73e-14 | 6.57e-01 | 0.2375 |
| 2954 | GSTZ1 | S016 | Human | Liver | HCC | 6.06e-17 | 5.26e-01 | 0.2243 |
| 2954 | GSTZ1 | C04 | Human | Oral cavity | OSCC | 1.12e-11 | 6.59e-01 | 0.2633 |
| 2954 | GSTZ1 | C21 | Human | Oral cavity | OSCC | 2.67e-16 | 6.56e-01 | 0.2678 |
| 2954 | GSTZ1 | C30 | Human | Oral cavity | OSCC | 1.31e-48 | 2.13e+00 | 0.3055 |
| 2954 | GSTZ1 | C43 | Human | Oral cavity | OSCC | 1.24e-21 | 5.32e-01 | 0.1704 |
| 2954 | GSTZ1 | C46 | Human | Oral cavity | OSCC | 5.85e-23 | 6.36e-01 | 0.1673 |
| 2954 | GSTZ1 | C51 | Human | Oral cavity | OSCC | 1.28e-15 | 9.40e-01 | 0.2674 |
| 2954 | GSTZ1 | C57 | Human | Oral cavity | OSCC | 3.48e-05 | 3.93e-01 | 0.1679 |
| 2954 | GSTZ1 | C06 | Human | Oral cavity | OSCC | 1.34e-08 | 1.47e+00 | 0.2699 |
| 2954 | GSTZ1 | C08 | Human | Oral cavity | OSCC | 2.77e-51 | 1.02e+00 | 0.1919 |
| 2954 | GSTZ1 | C09 | Human | Oral cavity | OSCC | 2.59e-03 | 1.42e-01 | 0.1431 |
| 2954 | GSTZ1 | LN22 | Human | Oral cavity | OSCC | 8.71e-05 | 5.15e-01 | 0.1733 |
| 2954 | GSTZ1 | LN46 | Human | Oral cavity | OSCC | 4.53e-12 | 5.88e-01 | 0.1666 |
| 2954 | GSTZ1 | LP15 | Human | Oral cavity | LP | 6.53e-04 | 9.30e-01 | 0.2174 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001943917 | Esophagus | HGIN | aromatic compound catabolic process | 105/2587 | 467/18723 | 1.89e-07 | 9.31e-06 | 105 |
| GO:190136117 | Esophagus | HGIN | organic cyclic compound catabolic process | 106/2587 | 495/18723 | 1.94e-06 | 7.13e-05 | 106 |
| GO:00067497 | Esophagus | HGIN | glutathione metabolic process | 20/2587 | 64/18723 | 2.63e-04 | 4.58e-03 | 20 |
| GO:199074820 | Esophagus | HGIN | cellular detoxification | 30/2587 | 116/18723 | 4.05e-04 | 6.15e-03 | 30 |
| GO:009723720 | Esophagus | HGIN | cellular response to toxic substance | 30/2587 | 124/18723 | 1.32e-03 | 1.57e-02 | 30 |
| GO:009886920 | Esophagus | HGIN | cellular oxidant detoxification | 25/2587 | 101/18723 | 2.29e-03 | 2.34e-02 | 25 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00065757 | Esophagus | ESCC | cellular modified amino acid metabolic process | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:000674912 | Esophagus | ESCC | glutathione metabolic process | 42/8552 | 64/18723 | 1.01e-03 | 5.12e-03 | 42 |
| GO:1990748110 | Esophagus | ESCC | cellular detoxification | 70/8552 | 116/18723 | 1.02e-03 | 5.17e-03 | 70 |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| GO:0097237110 | Esophagus | ESCC | cellular response to toxic substance | 72/8552 | 124/18723 | 3.65e-03 | 1.49e-02 | 72 |
| GO:0098869110 | Esophagus | ESCC | cellular oxidant detoxification | 60/8552 | 101/18723 | 3.76e-03 | 1.53e-02 | 60 |
| GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
| GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GSTZ1 | SNV | Missense_Mutation | c.148T>A | p.Phe50Ile | p.F50I | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GSTZ1 | insertion | Frame_Shift_Ins | novel | c.428_429insCC | p.Glu143AspfsTer14 | p.E143Dfs*14 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||||
| GSTZ1 | insertion | Nonsense_Mutation | novel | c.430_431insTGCGTTCCGAGAAGCTCTAGTTTCCA | p.Gln144LeufsTer7 | p.Q144Lfs*7 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||||
| GSTZ1 | SNV | Missense_Mutation | c.607N>T | p.His203Tyr | p.H203Y | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GSTZ1 | SNV | Missense_Mutation | rs774523538 | c.298N>T | p.Arg100Cys | p.R100C | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GSTZ1 | SNV | Missense_Mutation | c.20N>A | p.Ile7Asn | p.I7N | protein_coding | deleterious(0) | possibly_damaging(0.85) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | ||
| GSTZ1 | SNV | Missense_Mutation | rs866913315 | c.511N>A | p.Ala171Thr | p.A171T | protein_coding | deleterious(0.02) | benign(0.06) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| GSTZ1 | SNV | Missense_Mutation | rs750964006 | c.98N>T | p.Thr33Met | p.T33M | protein_coding | tolerated(0.11) | benign(0.011) | TCGA-CM-5863-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| GSTZ1 | SNV | Missense_Mutation | c.25N>C | p.Tyr9His | p.Y9H | protein_coding | tolerated(0.1) | probably_damaging(0.915) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| GSTZ1 | SNV | Missense_Mutation | novel | c.604N>C | p.Ser202Pro | p.S202P | protein_coding | deleterious(0) | possibly_damaging(0.779) | TCGA-AG-3742-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2954 | GSTZ1 | ENZYME, DRUGGABLE GENOME | dichloroacetic acid | 27143230 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |